Benitec Biopharma Inc. financial data

Symbol
BNTC on Nasdaq
Industry
Pharmaceutical Preparations
Location
3940 Trust Way, Hayward, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 832 % +143%
Debt-to-equity 13.7 % -67.9%
Return On Equity -60.3 % +73.3%
Return On Assets -53 % +66.5%
Operating Margin -22.6K % +62.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 10.6M shares +310%
Common Stock, Shares, Outstanding 17.9M shares +602%
Entity Public Float 8.37M USD +76%
Common Stock, Value, Issued 1K USD
Weighted Average Number of Shares Outstanding, Basic 10.6M shares +393%
Weighted Average Number of Shares Outstanding, Diluted 10.6M shares +393%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD
Research and Development Expense 14.8M USD +1.53%
General and Administrative Expense 7.64M USD +27.1%
Operating Income (Loss) -22.4M USD -9.97%
Nonoperating Income (Expense) 1.55M USD
Net Income (Loss) Attributable to Parent -20.9M USD -2.12%
Earnings Per Share, Basic -2.94 USD/shares +68%
Earnings Per Share, Diluted -2.94 USD/shares +68%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 67.8M USD +162%
Other Assets, Current 426K USD -11.6%
Assets, Current 68.3M USD +159%
Property, Plant and Equipment, Net 154K USD +126%
Operating Lease, Right-of-Use Asset 204K USD -55.9%
Other Assets, Noncurrent 56K USD -34.1%
Assets 68.8M USD +154%
Employee-related Liabilities, Current 495K USD +7.61%
Liabilities, Current 4.55M USD +0.42%
Operating Lease, Liability, Noncurrent 0 USD -100%
Liabilities 4.59M USD -3.18%
Accumulated Other Comprehensive Income (Loss), Net of Tax -993K USD -27.3%
Retained Earnings (Accumulated Deficit) -195M USD -12%
Stockholders' Equity Attributable to Parent 64.2M USD +188%
Liabilities and Equity 68.8M USD +154%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.59M USD -0.2%
Net Cash Provided by (Used in) Financing Activities 21.7M USD -22.4%
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 160M shares 0%
Common Stock, Shares, Issued 17.9M shares +602%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 17M USD -27.4%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 67.9M USD +162%
Deferred Tax Assets, Valuation Allowance 20.6M USD -6.06%
Deferred Tax Assets, Gross 21M USD -6.02%
Operating Lease, Liability 211K USD -57%
Depreciation 19K USD -54.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -21.1M USD -2.95%
Lessee, Operating Lease, Liability, to be Paid 215K USD -58%
Property, Plant and Equipment, Gross 1.58M USD +12.7%
Operating Lease, Liability, Current 211K USD -24.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 291K USD -3.96%
Lessee, Operating Lease, Liability, to be Paid, Year One 291K USD -1.36%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 4K USD -81%
Lessee, Operating Lease, Liability, to be Paid, Year Three 62K USD -18.4%
Deferred Tax Assets, Operating Loss Carryforwards 14.5M USD -21.3%
Unrecognized Tax Benefits 0 USD
Operating Lease, Payments 73K USD +7.35%
Depreciation, Depletion and Amortization 93K USD -17.7%
Share-based Payment Arrangement, Expense 1.17M USD +387%